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Abstract: Tissue damage, irrespective from the underlying etiology, destroys tissue structure and,
eventually, function. In attempt to achieve a morpho-functional recover of the damaged tissue,
reparative/regenerative processes start in those tissues endowed with regenerative potential, mainly
mediated by activated resident stem cells. These cells reside in a specialized niche that includes different
components, cells and surrounding extracellular matrix (ECM), which, reciprocally interacting
with stem cells, direct their cell behavior. Evidence suggests that ECM stiffness represents an
instructive signal for the activation of stem cells sensing it by various mechanosensors, able to
transduce mechanical cues into gene/protein expression responses. The actin cytoskeleton network
dynamic acts as key mechanotransducer of ECM signal. The identification of signaling pathways
influencing stem cell mechanobiology may offer therapeutic perspectives in the regenerative medicine
field. Sphingosine 1-phosphate (S1P)/S1P receptor (S1PR) signaling, acting as modulator of ECM,
ECM-cytoskeleton linking proteins and cytoskeleton dynamics appears a promising candidate.
This review focuses on the current knowledge on the contribution of S1P/S1PR signaling in the control
of mechanotransduction in stem/progenitor cells. The potential contribution of S1P/S1PR signaling in
the mechanobiology of skeletal muscle stem cells will be argued based on the intriguing findings on
S1P/S1PR action in this mechanically dynamic tissue.
Keywords: cytoskeleton; extracellular matrix (ECM); mechanotransduction; satellite cells;
sphingolipids; sphingosine 1-phosphate receptors (S1PRs); stem cells; skeletal muscle; stiffness;
tissue regeneration
1. Introduction
The capability of adult tissues to repair and regenerate after damage strictly depends on the
functionality of resident stem cells. In many different tissues endowed with regenerative ability, stem
cells mostly reside in a specialized local microenvironment, commonly referred as stem cell niche.
Although stem cell niches are distinctive for each tissue, they share many common features, providing
complex signals regulating stem cell maintenance and fate [1,2].
The niche includes different neighboring cells, dynamically and reciprocally interacting with
the stem cells, and the surrounding extracellular matrix (ECM) [1,2]. In healthy tissues, the niche
components essentially act to keep stem cells in a quiescent state preventing their premature
Int. J. Mol. Sci. 2019, 20, 5545; doi:10.3390/ijms20225545 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 5545 2 of 30
differentiation. By contrast, in injured tissues, the niche receives and releases biochemical and
physical signals, which contribute to the activation of the stem cells towards their proper functions.
In particular, stem cells exit their quiescent state to either proliferate, migrate to the site of injury or
differentiate towards the tissue specific cell phenotype, with the aim of morpho-functionally recover
the damaged tissues or of self-renewal, thereby ensuring the replenishment of the basal pool of resident
stem cells.
A growing body of evidence indicate that ECM is more than a passive support for stem cells,
providing instructive signals directing cell behavior [3,4]. Among others, the mechanical properties
of ECM, such as stiffness, markedly influence stem cell fate [5–13]. The cells are capable of sensing
mechanical stimuli from the surrounding microenvironment mainly thanks to the dynamics of several
surface components, defined mechanosensors, including, among others, transmembrane receptor,
focal adhesion (FA) proteins, transmembrane mechanosensitive channels and mechanosensitive
transcriptional factors. Subsequently, they can convert those stimuli into biochemical cascades leading
to gene/protein expression [9,14–16]. Within such an event, named mechanotransduction, a critical and
essential player is the actin cytoskeleton network, which links both physically and functionally the
mechanosensors to the nucleus [7,9,17–20]. Therefore, mechanical properties of ECM and cytoskeleton
dynamics are important co-participants in the definition of stem cell behavior/fate. It is worth
mentioning that mechanical forces of ECM affect the behavior of stem cells not only in terms of survival,
proliferation, migration and differentiation, but also in their ability to modulate, in a reciprocal manner,
the deposition, composition, rearrangement or removal of ECM and also to exert force on it. This with
the aim of maintaining the desired biomechanical properties of ECM, which enable stem cell proper
functionality [3,15,21]. The imbalance of this reciprocal relationship may have dramatic implications,
such as either insufficient (chronic) or aberrant fibrotic reparative response.
The identification of the factors and signaling pathways involved in the regulation of
mechanobiology of stem cell niche may open new paths for novel therapeutic target in the field
of regenerative medicine. In the last two decades, many studies have underlined the relevance of
sphingolipids, and in particular, of sphingosine 1-phosphate (S1P) as molecular modulators of the
behavior of various cells including stem/progenitor cells as well as of ECM-cytoskeleton linking protein
and cytoskeleton dynamic in several cell types.
This review, besides giving an updated description of sphingolipid metabolism and of the
signaling mediated by S1P and its specific receptors (S1PRs), focuses on the current knowledge on the
contribution of S1P/S1PR signaling in the control of mechanotransduction processes in different cell
types including stem/progenitor cells. In particular, the attention will be paid on the role of S1P/S1PR
signaling in cytoskeletal dependent phenomena such as FA assembly and lamellipodia formation,
implied in cell migration and transduction of signals from plasmamembrane to nucleus, and thus in
the control of cell fate. Novel mechanotransducers as targets of S1P/S1PR signaling, namely ezrin,
radixin, and moesin (ERM) family proteins and Hippo system, will be also considered. Part of this
review will be eventually devoted to the potential contribution of S1P/S1PR signaling in regulating the
mechanobiology of satellite cells, the widely regarded resident skeletal muscle stem cells, based on the
intriguing findings on S1P action in this mechanically dynamic tissue.
2. Sphingolipid Metabolism
Sphingolipids (SLs) are a class of natural bioactive lipids characterized by the sphingoid base
backbone, sphingosine (Sph). Since the last three decades, many studies have clearly indicated that
SLs are structural components of cell membrane as well as strong bioactive signaling molecules able to
control a variety of crucial cellular events, including signal transduction, cell growth, differentiation,
and apoptosis [22]. Genetic disorders of biosynthesis of SLs have been described, underlining the
relevance of these bioactive metabolites also in humans [23,24].
SL metabolism starts in response to various stimuli [25]. De novo biosynthesis initiates from
the condensation reaction of serine and palmitate catalyzed by serine palmitoyl transferase (SPT) in
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endoplasmic reticulum [26] to produce 3-keto-dihydrosphingosine, which, then, becomes reduced
to dihydrosphingosine and subsequently acylated by (dihydro)-ceramide synthase (also named
Lass or CerS) [27,28] to form dihydroceramide. Ceramide (Cer), generated by desaturation of
dihydroceramide [25] can be then deacylated by ceramidases (CDase) to generate sphingosine [29].
The reacylation of sphingosine that leads to Cer regeneration is named “salvage pathway” [25].
Sph can be also phosphorylated to generate S1P, which in almost all tissues can mediate crucial cellular
processes [25,30].
S1P formation is catalyzed by sphingosine kinases 1 and 2 (SphK1 and SphK2) [31], two isoforms
differently localized and regulated [32]. Indeed, SphK1 is mainly present in the cytoplasm and after
activation mediated by various stimuli, translocates to the cell membrane [32], whereas SphK 2 is
located in cell membranes and in organelles, mainly mitochondria and nuclei [33–35]. S1P can be
reversibly dephosphorylated to Sph by intracellular S1P phosphatases (SPPs) [36] and by extracellular
lipid phosphate phosphatases, or irreversibly degraded by S1P lyase (SPL) [37]. S1P degradation
by the S1P lyase is the end-point of all SLs. It is worth to underline that due to the presence of a
highly integrated network among various bioactive SLs, alterations of one single enzyme or sphingoid
molecules such as Cer and S1P, may contribute to changes in the content of the other sphingoids.
S1P/S1PR Signaling
S1P is a simple membrane-derived lysophospholipid with regulatory roles in almost all processes
of mammalian cells. However, the physiological functions of S1P in specific cell compartments, where
it is synthetized, are only partially understood. As a signaling biomolecule, S1P is peculiar since it
can act through both intracellular and extracellular mechanisms. Intracellularly synthetized S1P can
regulate specific targets [38], such as a highly conserved protein that regulates mitochondrial assembly
and function, namely PHB2 [39]. Moreover, histone deacetylases 1/2 (HDACs) and telomerase are also
some intracellular S1P targets [33,40]. S1P can also be transported outside the cell [41,42] by specific
transporters, such as the ATP-binding cassette (ABC) transporters family, Mfsd2b (major facilitator
superfamily transporter 2b) expressed in platelets and erythrocytes [43,44] and the transport spinster
homolog 2 (SPNS2) [45,46]. SPNS2 represents the master regulator of the secretion of S1P in most
mammalian cells exerting a special function in the development and homing of immune cells and in
bone homeostasis [47,48].
Extracellularly released S1P can promote pleiotropic biological functions by binding with its
specific heterotrimeric G-protein-coupled receptor subtypes, initially named Endothelial Differentiation
Gene (Edg) 1-5 and, actually, named S1PR1-5 [49–52]. Upon ligand activation, S1PRs couple with
diverse heterotrimeric G-protein subunits (Gαi, Gαq/11, Gα12/13), leading to different downstream
signaling pathways as extensively reviewed in literature [38,53,54]. S1PRs exhibit overlapping or
selective expression patterns in various cells and tissues: S1PR1-2 and 3 have a wide tissue distribution,
whereas S1PR4 is present mainly in lymphoid tissues, and S1PR5 is expressed predominately in
the nervous system. Interestingly, a shift in the content of each different S1PR subtypes has been
correlated to various biological processes [55], including skeletal muscle differentiation [56] as well as
cell degeneration, such as skeletal muscle cell atrophy [57].
In most mammalian cells, the balance of SPL and SPP activity controls S1P levels. In fact,
several in vitro as well as in vivo studies reported that SPL inhibition, promoted by genetic and
pharmacological downregulation, provokes S1P accumulation [58]. Interestingly, under physiological
conditions, circulating S1P levels are significantly higher (10−7–10−6 M range) in peripheral blood
than in solid tissues due to the release of S1P by several blood cell types [44,59–62] and to the lack of
SPL expression in platelets [63] and of SPL and SPPs expression in erythrocytes [64]. In peripheral
blood, S1P binds to albumin and apolipoprotein M and circulates as a part of high-density lipoprotein
particles. On the other hand, the degradation of S1P by SPL at tissue level contributes to the low level
of the bioactive lipid outside of the bloodstream [65].
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Notably, the difference in the concentration levels of S1P in blood and in the tissues drives the
migration of immune cells [47] as well as of stem/progenitor cells [66]. S1P acting as chemoattractant,
is responsible for the attraction of immune cells and their exit from lymphoid organs to circulation
and for the passage of the bone marrow progenitor cells from peripheral tissues to the lymphatic
system [67]. These S1P functions appear physiologically relevant in the control of the immune system
during inflammation as well as in the in vivo physiology of vascular systems. Among the various S1PR
subtypes, the S1PR1 expression is the critical factor that regulates sensitivity to circulating S1P. In fact,
abrogation of S1PR1 expression prevents lymphocyte egress and reduces inflammation [68]. On the
contrary, S1PR2 antagonizes migration elicited by chemokines, contributing to relegate immune cells
within the tissues [69].
3. S1P/S1PR Signaling and Mechanotransduction
Mechanical forces, generated from the ECM environment, drive biochemical signals and
molecular interactions resulting in actin cytoskeleton and cell membrane remodeling. In particular,
the progressive and successive cycles of cell adhesion, contraction and retraction mediated
by movement-associated membrane protrusions, including among others lamellipodia, are the
consequences of mechanotransduction events that control cell movement and cell shape. In fact,
mechanical stimulation of distinct adhesion proteins contributes to their conformational changes
and membrane modifications that, in turn, promote the recruitment of other scaffolding proteins.
These events lead to the maturation of nascent FA complexes, premise of the cell migration.
Similarly, mechanical cues promote structure changes of some proteins, such as talin, crucially
involved in the signaling transduction upstream to gene expression regulation, thus controlling the
cell fate determination [70,71].
3.1. Impact of S1P/S1PR Signaling in Cytoskeleton Remodeling/Dynamics for Cell Migration
Emerging evidence indicate that S1P signaling and the S1PR expression profile, are crucially
implicated in the movement-associated membrane transformation (i.e., cell adhesion structure
variations, lamellipodia formation etc.) as well as in cytoskeleton remodeling leading to cell migration
in response to stimuli from the ECM. The conversion of mechanical forces to biochemical signals
requires several structures including the FA complexes, which are organized around of specific receptor
proteins, the integrin family proteins, binding to ECM and to actin-coupled complex functioning as
anchor proteins. Some evidence seems to indicate that integrins can also act as mechanosensors [72].
3.1.1. Focal Adhesions
The first step of cell migration is the dynamic change of FAs. In response to mechanical tension,
the recruitment of proteins, such as vinculin and α-actinin, is responsible for size increase of FAs [73].
Successively, FAs tightly associate with the end of stress fibers, which are contractile structures crucially
implicated in pushing the cell body [17] accompanied by disassembly of FAs and cell retraction at
the trailing edge. The role of S1P/S1PR1 signaling in FA formation has been described in fibroblasts
several years ago. In particular, it has been shown that S1P/S1PR axis is required for platelet-derived
growth factor (PDGF)-induced FA formation and activation of FA kinase (FAK)/Src and p38 MAPK [74].
S1P-augmented fibroblast chemotaxis via Rho-associated protein kinase (ROCK) activation appeared
to be also mediated by S1PR2 activation [75].
S1P through its receptors acts mainly by promoting the co-localization of cortical actin, stress
fibers, FA complexes and FAKs [76]. From a molecular point of view, it has been documented that S1P
is able to induce tyrosine phosphorylation of FAK, leading to FA disruption and cell-to-matrix and
cell-to-cell adherens junctional complex remodeling [77,78] as well as to tyrosine phosphorylation of
paxillin, a multifunctional and multidomain FA adaptor protein [79]. However, studies specifically
addressing the role of the other S1PR subtypes in FA formation are still scanty.
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Although the role of the interaction between integrins and ECM and the their role in
mechanotransduction is beyond the purpose of this review, it is important to underline that very recently
it has been reported a functional cross-talk between integrin co-receptor CD98hc (SLC3A2) and SL
metabolism, which contributes to cell mechanical homeostasis [80]. CD98hc, a transmembrane protein
that associates with integrinsβ1/β3 without any effect on their activation, can regulate integrin-mediated
mechanosensing by controlling the level of the delta-4-desaturase (DES2), the enzyme that converts
D-erythro-sphinganine to D-erythro-sphingosine. In fact, the depletion of CD98hc decreases the
expression of DES2 and reduces SL availability, thus preventing correct membrane remodeling and
RhoA-mediated signaling activation, and in turn leading to stiffness sensing impairment.
Another interesting role is played by SLs in endothelial cells (ECs). In particular, in this type of cells,
S1P and other factors, such as the hepatocyte growth factor (HGF), can act as barrier-enhancers [81,82].
The relevance of S1P/S1PR system is confirmed by the findings that impairment in S1P signaling and
barrier integrity disruption has been observed in pathological conditions, such as several pulmonary
disorders [83]. The protective action of S1P on blood vessels is the result of S1PR activation and the
subsequent intricate crosstalk with other signaling molecules, such as MAPKS and ROCKs. The EC
barrier enhancement has been mainly attributed to the activation of S1PR1/Rac pathway. Contrarily,
the binding of S1P to another S1PR subtype, S1PR3, promotes barrier disruption and loss of tight
junction formation. Additional studies demonstrated that the signaling promoted by S1PR3 leads
to vasodilation through endothelial nitric oxide synthase activation in arteries [84]. Differently to
S1PR1, S1PR2 gene disruption promotes the decrease of vascular permeability by affecting endothelial
tight junctions, indicating a positive role of the signaling triggered by this receptor subtype [85–87].
The dissimilar functions of the S1PRs are due to the specific coupling with different G-proteins: S1PR1
couples solely with Gi/o, whereas S1PR2 and S1PR3 also couple with G12/13 inducing the stimulation of
RhoGTPase, and, in turn, cortical actin destabilization, stress fiber formation, and endothelial barrier
disruption. It has also been reported that in the microvascular endothelial model, the bioactive lipid
may regulate the EC barrier permeability through S1PR1 as well as S1PR2 signaling [88]. On the other
hand, a role for S1PR5 has been proposed in ECs localized in the central nervous system, where its
silencing results in the reduction of leukocyte migration. This finding suggests that S1P/S1PR5 signaling
may control barrier disruption and permeability during inflammation in the nervous system [89].
Interestingly, a recent clinical study reported that in patients with SphK1-positive colorectal cancer,
S1P formation is correlated to enhanced cell migration and metastasis with a worse prognosis with
respect to patients that are affected by SphK1-negative cancer [90]. As demonstrated in this study [90],
SphK1/S1P may control through S1PR signaling the expression of phospho-FAK, p-protein kinase B
(AKT) and cytoskeleton reorganization.
3.1.2. Lamellipodia
The first evidence of a role of S1P in lamellipodia formation was reported by Stam et al. [91].
In this report, it was shown that T-lymphoma invasion is due to LPA/S1PR-mediated RhoA and
phospholipase C signaling pathways, which lead to pseudopod formation and enhanced infiltration.
In the last two decades, the regulation of membrane protrusion formation by S1P/S1PR signaling has
been shown in many circumstances and cell types [92–94]. Because of the difference in the expression
of S1PR subtypes coupled to distinct GTP-binding proteins, S1P may induce opposing effects, either
stimulatory or inhibitory, on cell migration and homing of various types of progenitor cells [95], such
as bone marrow derived-mesenchymal stromal/stem cells (MSCs). In particular, it has been shown
that the receptor subtypes, S1PR1 and S1PR3, are responsible for S1P-induced migration of human
MSCs, whereas S1PR2 mediates its inhibition, activating Rho/ROCK system [96]. The bioactive lipid
potently stimulates motility of ECs [97] and migration of keratinocytes [98], suggesting a positive role
of the bioactive lipid on cutaneous wound closure. S1P is also a potent cell migration inducer for some
tumor cells, such as glioma cells [99,100]. Contrarily, S1P exerts inhibitory effect on the melanoma,
fibrosarcoma [101] and breast cancer cell migration [102].
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Recently, it was reported that the formation of complexes between proteins involved in SL
metabolism and membrane modifications is crucial for cell migration [103]. In fact, on the lamellipodia
side, SphK1 and the receptor S1PR1 form a complex with filamin A, an actin-binding protein that
is known to cross-link cortical actin filaments at membrane ruffles. In line with this, other novel
findings indicate that the cytoskeletal components, such as cortactin and non-muscle myosin light
chain kinase, assemble with S1PRs. In particular, this event occurs in caveolin-enriched microdomains
(CEM), where integrin β4 forms a complex with S1P-activated S1PR1 [104], suggesting the importance
of protein-protein interactions and localized S1P production. Furthermore, it is worth to note that a
specific membrane localization and protein assembly of S1PRs not only contribute to lamellipodia
formation/cell migration, but also permit specific signaling pathways. In fact, it has been recently
demonstrated that extracellular α-Synuclein can provoke mislocalization of the receptor subtype
S1PR1 out from CEM. This event induces the uncoupling of S1PR1 from Gi protein that, in turn, leads
to the increase in α-Synuclein content. Therefore, the impairment in S1PR1 localization/signaling
may contribute to the protein accumulation and aggregation, characteristic features of idiopathic
Parkinson’s disease [105].
Based on the relevance of released S1P and its action through S1PR signaling on membrane
protrusion formation and remodeling, cytoskeleton rearrangement and cell migration, several
therapeutic strategies have been developed [106]. In particular, clinical and preclinical studies
have reported that S1P analogues may be useful as protective factors especially in inflammation
and autoimmune disorders. Fingolimod (FTY720) is the first S1PR modulator clinically approved
as first-in-class drug targeting S1PR. Although the clinical relevance of Fingolimod is clear, the
mechanism of action of this drug is not fully clarified. It is known that it is phosphorylated in vivo after
ingestion. In lymph nodes, the drug initially activates S1PR1 and then induces its internalization. Thus,
the cells appear less sensitive to the S1P gradient and remain within the lymph node [107,108].
S1PR1 agonist/antagonists are mainly exploited in pluripotent multilineage hemopoietic cells.
The antagonist of S1PR1, W146, significantly stimulates the in vivo mobilization of Kit+/Sca-1+/Lin−
hematopoietic stem progenitors from bone marrow into the blood, suggesting the involvement of this
receptor subtype in keeping hematopoietic cells inside the origin microenvironment [109]. In addition,
since hematopoietic stem and progenitor cells present higher levels of S1PR3 in comparison to
differentiated cells, and this receptor subtype is crucial for niche localization, it has been demonstrated
that the pharmacological antagonism (e.g., VPC01091) or the knockout of S1PR3 mobilizes these cells
into blood circulation [110]. The role of S1PR2 in neural progenitor cells has also been determined
by Kimura et al. [111]. The authors demonstrated that the blockade of S1PR2 by JTE-013 improves
the migration of these progenitor cells in response to a S1P gradient. It is worth to note that the
S1P analogues not always mimic the effects of endogenous S1P. For instance, S1P and FTY720
act differently in promoting EC barrier enhancement: only S1P promotes calcium increase and
S1PR1 phosphorylation, whereas phospho-FTY720 does not induce Rac1 activation or cortactin
phosphorylation [112]. Interestingly, other more selective S1PR modulators have been synthetized
and subjected to clinical trials [113]. For example, FTY720-phosphonate has been shown to activate
Rac1, induce FA formation and redistribution of actin and cortactin in cell periphery of lung ECs,
mimicking S1P effects [114]. In line with these data, the treatment with a novel S1PR5 antagonist,
BIO-027223S1PR5, demonstrated that S1PR5 is fundamental for human natural killer cell migration
and for the exit of these cells from the bone marrow to the blood circulation [115].
3.2. Impact of S1P/S1PR Signaling in Cytoskeleton Remodeling/Dynamics for Cell Fate
Important physiological adjustments in cell adhesion, cytoskeleton remodeling and functional
protein interactions are crucial during cell differentiation in response to mechanical properties of
ECM [6,7,11,116,117].
Cytoskeleton dynamics and rearrangement of its components, such as actin filaments, arise when
stem cells start to differentiate into cells of a specific lineage. For instance, few FAs and dispersed
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actin filaments facilitate the adipogenic differentiation of MSCs, whereas higher number of FAs and
well-organized cytoskeleton promote their commitment into osteoblasts [118]. It has also been reported
that disrupting actin depolymerizing factors (i.e., Cofilin 1) reduces the ability of MSCs to undergo
adipogenesis, while the treatment with the actin polymerization inhibitor, such as Cytochalasin D,
potentiates cell differentiation, confirming the existence of a link between cytoskeleton organization
and MSC lineage commitment [119].
The meaning of this biomechanical regulation for the tissue repair/regeneration is also proven
by the pathological consequences of ECM/cytoskeleton dysregulation. In fact, when the mechanical
properties of tissue are impaired, the effects are considerable: mutations in the genes encoding
intermediate filament proteins are associated with pathologies even in humans, including amyotrophic
lateral sclerosis [120,121]. In addition, mutations in desmin, filamin C, etc., increase the stiffness and
limit the tolerance to mechanical stress in skeletal muscle fibers leading, in some cases, to myofibrillar
myopathies [122]. Changes in mechanical properties may also lead to cell transformation. It was,
in fact, reported that altered tissue stiffness could disturb morphogenesis and guide epithelial cells
towards a malignant phenotype [123].
Several lines of evidence underline the role of S1P/S1PR signaling in the modulation of MSC
differentiation via cytoskeleton remodeling. For instance, the inhibition of the S1PR2-mediated
signaling, leading to ERK phosphorylation and actin rearrangement, determines MSC clonogenicity
and migration, while decreasing cell differentiation into adipocytes and mature osteoblasts [96]. It is
known that S1P/S1PR signaling can also increase the expression of cardiac lineage and smooth muscle
markers in c-kit+ cardiac progenitor cells. In particular, it seems that S1PR2 and S1PR3 expressed
in cardiac progenitor cells can trigger Gα12/13/RhoA signaling affecting the commitment of these
progenitor cells. Therefore, the downstream signaling to these S1PR subtypes may be crucial in
favoring the tissue response to injury [124]. In addition, very recently, a study performed in osteocytes
have established the role of S1P metabolism in the control of bone mass and architecture when
the cells are subjected to interstitial fluid flow [125]. In fact, a downregulation of S1P transporter
SPNS2, and of the enzymes responsible for degradation and dephosphorylation of S1P, occurs in
response to this mechanical loading, thus suggesting a functional link between S1P metabolism and
cell mechanotransduction [125]. It is worth to note that the importance of the biomechanical properties
of ECM in the process of cell differentiation has been underestimated and misunderstood by culturing
the cells on stiff substrates, with traditional methods. For instance, Berdyyeva et al. [126] reported that
primary epithelial cells cultured in plastic dishes increase in the stiffness with passaging. Similarly,
when epithelial breast cancer cells and endometrial adenocarcinoma cells are cultured on glass and
plastic surface, respectively, were found to stiffen and express more α-actin, confirming the influence
of the culture surface and conditions on cell fate decision [127].
Although it is beyond the scope of this review, here, we only underline the importance to
consider carefully the crucial point of cell culture conditions especially in order to better understand the
spatio-temporal relations between cells, matrix and soluble factors, such as S1P, in the three-dimensional
niche. Furthermore, because cytoskeleton has a role in mechanotransduction and its structural
components are very dynamic, it can be speculated that the cytoskeleton may be a “memory storage of
cell shape”. Interestingly, it is known that actin structures remain after mitosis and some stress-fibers
persist in daughter cells [128].
Further research is needed to better understand how the signaling starting from plasmamembrane
can contribute to conserve the cytoskeleton organization and influence cell fate. Interestingly, as stated
more extensively in the Section 4.2, a correlation between cell shape changes in response to mechanical
forces and gene expression regulation has been proposed to occur via the Hippo system, which is also
a specific mechanotransducer target of S1P /S1PR signaling.
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4. Mechanotransducers as Targets of S1P/S1PR Signaling
As stated above, the simultaneous expression/activation of several S1PR subtypes in one cell and
the coupling of each subtype to various G-proteins lead to specific and complex responses [129,130].
Several mediators of mechanical inputs are also effectors in the multiple signaling pathways triggered
by S1P/S1PR system. Thus, focusing on the specific object of this review, here we consider only some
novel mechanosensors/transducers as targets of S1P/S1PR signaling: the ezrin, radixin and moesin
(ERM) protein family [131] and the Hippo system [14,132].
4.1. ERM Protein Family
Ezrin, radixin and moesin are the components of ERM protein family [133]. They are scaffolding
proteins able to link directly the plasmamembrane to the cortical actin through Rho GTPases [131,134].
By mainly interacting with cadherins and integrins, ERM proteins contribute to the communication
cell-ECM as well as cell-neighboring cells, thus acting as mechanotransducers. Moreover, ERM proteins
are able to act as anchor proteins for localizing proteins, close to their targets (i.e., protein kinase
A) and facilitating membrane transport of electrolytes through the regulation of ion channels and
transporters [135]. Thereby, ERM proteins play an important role in the regulation of several biological
processes such as cell morphology [134], cell adhesion [136] plasmamembrane protrusion formation
and, thus, cell migration [137]. It has been also documented that ERM protein family can influence
stem cell differentiation by regulating cell stiffness and reorganizing FAs. For instance, it has been
reported that ERM knockdown determines reduced actin disassembly and cell stiffness, thus leading to
a time-dependent impairment of adipogenesis process [138]. Notably, ERM protein family dysfunctions
are also associated with several cancer types, such as osteosarcoma [139] and breast cancers [140].
The activation of ERM proteins is controlled by conformational changes. When activated, the
protein structure shifts from the inactive state, characterized by cytosolic localization, to the active
one, marked by plasmamembrane localization due to the phospatidylinositol 4, 5-bisphosphate
binding at amino-terminus of the protein and the phosphorylation of the carboxyl-terminus. In the
literature, few protein kinases are described to be able to phosphorylate ERM proteins in vivo, such as
PKC, G protein-coupled receptor kinase 2 and the myotonic dystrophy kinase-related Cdc42-binding
kinase [141].
Importantly, several reports indicate that SLs and, in particular S1P, can regulate ERM family
protein activation in many cell types, including tumor cells, such as breast cancer and glioblastoma
cells [142] as well as chondrogenic cells [143]. The first evidence of the role of SLs in ERM protein
functions was obtained by Zeidan et al. [144]. The authors demonstrated that the disruption of the
acid sphingomyelinase/Cer pathway contributes to prevent cisplatin-induced cytoskeletal changes
and ezrin dephosphorylation. In another study, S1P, acting through S1PR2, was found to be able to
promote strongly the C-terminal phosphorylation of the ERM proteins in HeLa cells transfected with
recombinant bacterial sphingomyelinase, influencing actin cytoskeleton remodeling and filopodia
formation [145]. Similarly, in human embryonic fibroblasts, the S1P/S1PR2 signaling is important to
regulate cellular architecture through the modulation of ERM protein phosphorylation [146]. In HeLa
cells, it has been documented that S1P, specifically formed by SphK2 and not by SphK1 activity,
is essential for cell invasion elicited by epidermal growth factor [147]. In fact, the increased S1P
production, achieved by overexpression of SphK2, likely in a specific cellular compartment, is sufficient
in promoting ERM protein activation. SphK/S1P system via ERM protein activation has also been
shown to regulate phosphate-induced vascular smooth muscle cell matrix mineralization, suggesting
new potential therapeutic approach for inhibiting or delaying vascular calcification [148]. ERM proteins
are also modulated by S1P in human pulmonary ECs, where they contribute to the function of S1P as
barrier-enhancer [149].
Interestingly, in this study, it is shown that, although the ERM proteins are structurally similar,
each one can differently affect the modulation of S1P response, in terms of cytoskeleton remodeling
and permeability. In T cells lacking moesin, S1P fails to promote the S1PR1 internalization and
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clathrin-coated vesicles formation, supporting the importance of this specific protein as scaffold.
Furthermore, when these moesin-deficient T cells were treated with FTY720 a delay in lymphopenia
was observed, indicating a distinct function of this protein in regulating S1PR1-mediated signaling [150].
Moreover, S1P promotes the phosphorylation/activation of ezrin [146,147] and in a PKC-dependent
manner, the bioactive lipid stimulates pulmonary ECs via the activation of ezrin and moesin, but not
of radixin [151].
4.2. Hippo System
Emerging evidence indicate that the mechanical properties of ECM can be transduced from the
plasmamembrane to the nucleus by a direct mechanocoupling through cytoskeleton [152–154]. Indeed,
it has been reported that actin cytoskeleton disruption, promoted by pharmacological or genetic
approaches, can induce changes in nuclear morphology, lamin A/C expression, chromatin dynamics,
histone post-translation modifications and then in gene transcription [155]. In these mechanobiological
responses, the nuclear envelope proteins can play a central role [156]. It has been described that ECM
stiffness acts as upstream regulator of a signaling pathway named the Hippo pathway [132], which
was firstly described in Drosophila in a genetic mosaic screen finalized to the identification of genes
involved in the growth of larval tissues [157].
The main components of the Hippo system in mammalian cells are the transcription factor YAP
(Yorkie homologous Yes protein-tyrosine kinase-associated protein), the co-activator TAZ (PDZ-binding
motif) and their upstream regulators represented by the tumor suppressive kinases Mst1/2 and
Lats1/2 [132].
The role of YAP/TAZ as mechanotransducers of the information either from cell shape or from the
ECM to the nucleus are reported in several studies [14,158–160]. In particular, ECM stiffness controls
the kinase cascade and, in turn, the shift between the active/inactive state of YAP. When the cell is
round-shaped, due to less stiffer or smaller ECM adhesive area, the tyrosine-phosphorylation of YAP
facilitates its cytoplasmic localization and its degradation by proteasomes. Therefore, when YAP/TAZ
is out of the nucleus, the gene transcriptional activity is off, cells arrest in G0 and enter the commitment
program. Contrarily, when cells are plated on large and stiff substrates, the Hippo pathway is inhibited
due to the high cytoskeletal tension mediated for example by ROCK. Therefore, when YAP/TAZ, are in
the dephosphorylated state, accumulate into the nucleus promoting cell proliferation and inhibiting
cell differentiation [14].
Similarly, the contact inhibition promotes YAP/TAZ phosphorylation and cytosolic localization.
On the other hand, at low density, cells divide and active YAP/TAZ localizes into the nucleus, functioning
as pro-proliferative transcriptional factors. Target genes of YAP/TAZ activity including connective
tissue growth factor (CTGF) have been described [14,161].
Recent studies demonstrated that the stimulation of some G protein-coupled receptors (GPCRs),
such as S1PRs, controls YAP activity [132]. It has been shown that S1P/S1PR2 signaling determines a
strong dephosphorylation and activation of YAP/TAZ leading to CTGF expression and proliferation
increase in hepatocellular carcinoma cells [162]. S1PR2-mediated signaling activates YAP proteins in
ovarian cancer cells favoring their proliferation [163,164]. Interestingly, HEK 293T cells transfected with
the S1PR2 (R150H) mutant show receptor retention into intracellular vesicles, the block of G-protein
coupling and low Hippo activity [165].
However, it is worth to note that, in several circumstances, S1P/S1PR signaling seems to be
independent from the Hippo pathway kinases. In fact, it is known that the bioactive lipid also induces
YAP nuclear localization through the G12/13- or Gq/11-coupled S1PR2, Rho GTPase activation and F-actin
polymerization [163]. Moreover, by bioinformatic analysis, it has been demonstrated that YAP signature
gene expression panel is significantly higher in tissue samples obtained from S1P lyase-deficient mice,
indicating that the accumulation of S1P may regulate the YAP function in vivo [163]. In the same
study, it has been also shown that serum starvation of HEK293A cells disrupts actin stress fibers
and forces YAP into the cytoplasm. Interestingly, these events can be counteracted by S1P treatment.
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Notably, another SL, sphingosylphosphorylcholine, affects YAP activity [166]. Since YAP/TAZ are
important regulators of the cell cycle, they play a crucial role in stem cell determination and tissue
regeneration. For instance, high stiffness, elevating YAP/TAZ, determines bone differentiation of MSCs,
whereas a lesser tough environment inactivates YAP/TAZ and allows cell commitment into other cell
lineages, such as adipocytes [14]. Interestingly, YAP/TAZ activity is repressed when the integral type I
endopeptidase MT1-MMP (Membrane type I-matrix metalloproteinase) is knockout, preventing MSC
differentiation in osteocytes, thus, leading to osteopenia [167]. Despite the scanty evidence, based on
the relationship between actin cytoskeleton, YAP/TAZ activity and S1PR-mediated signaling, important
consequences on stem cell fate can be expected. In fact, the YAP target genes are transcripted in human
embryonic stem cells after treatment with exogenous S1P [168]; the treatment with the bioactive lipid
is able to promote follicle growth by increasing nuclear YAP, thus, suggesting a potential role for S1P
analog in polycystic ovarian syndrome treatment [169]. Moreover, S1P can regulate cardiac precursor
cell migration by controlling YAP signaling, playing a role in endoderm formation in organism model
Zebrafish [170].
Based on this emerging evidence that YAP is a downstream effector of some biological functions
of S1P, further investigation of the crosstalk between YAP/TAZ and S1P/S1PR signaling may open new
insights on the functional relationship of these two pathways.
5. Mechanobiology of Skeletal Muscle Stem Cell Niche: The Potential Role of
S1P/S1PR Signaling
Several studies in the last years underlined the role of S1P/S1PR signaling pathway in skeletal
muscle biology, including resident skeletal muscle myogenic precursor/satellite cell proliferation,
differentiation and migration. By contrast, to date, no data are available on the involvement of this
signaling pathway in the regulation of mechanobiology of satellite cell niche namely: (1) satellite
cell mechanotransduction events in response to ECM stiffness and (2) modulation of ECM stiffness.
However, it appears intriguing to postulate this involvement when considering that: (1) skeletal muscle
tissue is highly mechanically dynamic and, therefore, satellite cells are expected to experience strong
mechanical forces during each routine contraction-relaxation cycle and, also, to gauge the intrinsic
mechanical properties of surrounding ECM; (2) experimental evidence addressed the role of S1P/S1PR
signaling as molecular modulators of ECM cytoskeleton-linking protein and cytoskeleton dynamics in
satellite cells as well as of the functionality of different cells involved in ECM building.
5.1. Satellite Cell, Interstitial Cell and ECM Dynamic Interplay
It is well accepted that skeletal muscle tissue possesses a remarkably intrinsic ability to regenerate
after focal damages, mainly thanks to the activity of the satellite cells, widely regarded as the resident
muscle stem cells [171,172].
In healthy skeletal muscle, satellite cells reside mitotically quiescent and transcriptionally inactive
in an unique and specialized anatomic microenvironment at the periphery of differentiated myofibers
(hence the name) in intimate association with the myofiber sarcolemma underneath the basal lamina,
known as satellite cell immediate niche [173]. By contrast, in injured muscle, satellite cells exit the
quiescent state becoming activated to execute the myogenic program, reminiscence of what occurs
during embryogenesis, culminating in the formation of new polynucleated myofibers capable to
morpho-functionally recover the damaged tissue [174]. There is evidence suggesting that, in parallel, a
small percentage of satellite cells undergo to self-renewal thereby ensuring the replenishment of the
basal pool of resident satellite cells, ready for responding to future demands [175].
As for other stem cells in different tissues, the functionality of satellite cells is strictly dependent
on the features of the surrounding microenvironment, which, beside the immediate niche, includes the
microenvironment beyond. The latter may be identified by the interstitial space between myofiber,
where different interstitial cells, motor neuron endings, vascular network with associated secretable
factors are located, embedded in the ECM. Moreover, the systemic milieu has to be included, comprising
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molecular and cellular signals deriving from the entire muscle belly along with neighboring skeletal
muscles and bones, immune cells and circulating factors including among others gastrointestinal tract
hormones [173,176].
Growing evidence indicated that critical factors for the regulation of satellite cell activation and
myogenic differentiation are represented by: (1) juxtacrine and paracrine interactions that satellite
cells establish with some resident or migrated interstitial cells [171]. In particular, a role in supporting
satellite cell-mediated regeneration has been documented for interstitial cells, such as pro-inflammatory
phagocytic macrophages (M1) and anti-inflammatory pro-regenerative macrophages (M2), fibroblasts,
myofibroblasts, different MSCs including fibro-adipogenic progenitors (FAPs), telocytes and capillary
endothelial and periendothelial cells including perycites [171,177]. (2) Intrinsic biomechanical features
of ECM embedding the cells such as stiffness [178–182].
ECM of satellite cell microenvironment includes essentially the basement membrane and the
overlying endomysium sheath, intimately linked to it, surrounding each myofiber to form the interstitial
stroma. The basement membrane is composed of two layers: one internal, linked to the sarcolemma,
called basal lamina, wrapping the underlying satellite cells, and a second, external, namely fibrillar
reticular lamina. The main ECM components are represented by non-fibrillar type IV collagen, fibrillar
type I and III collagen closely assembled to form collagen fibers, assorted glycoproteins, mostly serving
as cell adhesion molecules, embedded within an amorphous proteoglycan-rich ground substance.
For a more detailed description of components of ECM surrounding satellite cells, we refer to the
following reviews [178,183,184].
The content in fibrillar collagen is the main determinant of ECM stiffness. Such property measures
the resistance to deformation; in other words, it may be defined as the resistance of collagen fibers to
breakdown under mechanical forces during stretching [12,15]. Several in vitro studies showed that
myogenic differentiation of satellite cells requires an optimal ECM stiffness and that either lesser or more
stiff coatings negatively affect the ability of myogenic cells to proliferate and differentiate [179,185–187].
An interesting study showed that collagen VI null murine muscles display a significant decrease in
stiffness, which correlates with an impairment of the in vitro and in vivo activity of satellite cells [188].
In addition, it has been demonstrated that the impairment of satellite cell functionality and reduced
regenerative capacity in aged or pathological muscles is associated with an increase of intrinsic ECM
stiffness [182,189–193].
It is clear that ECM stiffness is related to the activity of the embedded cells, responsible for the
constant collagen deposition, degradation (by secreting different MMPs) organization/reorientation
or cross-linking. These cells are mainly represented by resident interstitial fibroblasts and
myofibroblasts [15,194]. However, many other cell types present in the satellite cell microenvironment
may contribute to ECM turnover/stiffness including the same satellite cells, interstitial MSCs and
infiltrating inflammatory cells [195,196].
Satellite cells may employ different mechanosensors to perceive the stiffness of ECM including,
among others, integrins-FA complexes linked to actin cytoskeleton, mechanosensitive channels and
mechanosensitive transcriptional factors, such as the Hippo pathway effectors, which have been
demonstrated to be able to modulate the myogenic transcriptional events in response to mechanical
cues [14,179,182,197–200].
It worth highlighting that the satellite cell microenvironment, and similarly other stem cell niches,
is a very dynamic compartment where the cell population that interacts with satellite cells, as well as
the ECM stiffness, differ under homeostatic quiescent conditions with respect to repair/regeneration
after a damage [1,174,178,201,202]. It is likely that in a physiological tissue repair after a focal damage,
the modifications that occur in the microenvironment are compliant with stem cell proper functionality
and favorable for assuring their successful myogenic differentiation, leading to the morpho-functional
recovery of damaged muscle tissue as well as self-renewal to replenish the satellite cell pool. After tissue
damage, immune cells (mainly neutrophils and macrophages) are recruited, transiently infiltrate the
satellite cell microenvironment and, together with degenerated or necrotic myofibers, firstly convey
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biochemical signals for the activation of satellite cells. “Nursing” interstitial cells also contribute to
modulate satellite cells activities [177,201]. With regards to the ECM immediately surrounding satellite
cells, a focal muscle damage frequently causes its initial insult, followed by a further physiological
degradation by MMPs [178], likely reducing the intrinsic ECM stiffness. This appears essential to allow
both the migration of satellite cells and the homing of inflammatory cells to the site of injury and also
the release of ECM-tethered pro-myogenic factors. On the other hand, it is worth saying that signals
from such a damaged microenvironment mainly activate resident MSCs, fibroblasts and myofibroblasts.
These cells are responsible for the collagen deposition forming a provisional contractile scar required
to rapidly restore tissue integrity and preserve organ function [194,203]. Consequently, ECM stiffness
undergoes a transient increase, in line with data in the literature [181,189,202,204], but however, it
results still conductive for the accomplishment of satellite cell mediated-regeneration mechanisms.
The scar will be ultimately removed and replaced by normal tissue. By contrast, in case of a persistent
or extended damage or in the presence of a persevering inflammatory stimuli, it is possible to assist to
a prolonged and excessive ECM accumulation and stiffening, compromising the achievement of tissue
regeneration and leading to permanent tissue scarring [10,21,178,194,202,203].
5.2. Potential Impact of S1P-S1PR Signaling on Satellite Cell and Neighboring Interstitial Cell Functions
and Interplay
Dynamic changes in S1P metabolism and signaling after a muscle damage or disease/myopathy
have been documented, suggesting a role for this biolipid in influencing the endogenous mechanisms
of tissue repair/regeneration [205–209]. It is conceivable that resident satellite cells may be target
of circulating/systemic S1P. Indeed, the capability of S1P/S1PR mediated signaling pathway to
modulate proliferation, migration and differentiation of different muscle progenitor/myogenic cells and
muscle regeneration in vivo [206,209–212] and ex-vivo/in vitro [205,207,211–224] has been documented.
In addition satellite cells, differentiated myofibers and interstitial cells, such as MSCs and macrophages,
could also locally release S1P, which may act via S1PRs in a autocrine and paracrine manner for
regulating cell behavior [205,225,226] (Figure 1).
In this line, a study of our research group demonstrated that the activity of SphK1, the kinase that
catalyzes the formation of S1P, is required for the myogenic differentiation of C2C12 myoblasts. Indeed,
SphK1 activity, SphK1 protein content and S1P formation were found to be enhanced in differentiating
myoblasts. Moreover, it was also reported that myogenesis in SphK1-overexpressing myoblasts was
abrogated by treatment with short interfering RNA specific for S1PR2 [218] suggesting that the locally
synthetized S1P mediates the myogenic differentiation events after its release and interaction with
receptor, thus indicating the pro-myogenic role of S1P/S1PR signaling.
To support the involvement of myofiber-released S1P and S1PR axis in myogenic events, recent
findings demonstrated a down regulation of SphK1 activity, an increased expression of S1P transporter
SPNS2 and S1PR2 in myotubes induced to atrophy by dexamethasone, thus indicating a negative role
of S1P/S1PR2 axis in the maintaining of normal mature myotube phenotype [57].
Our research group has also demonstrated the capability of bone marrow-MSCs to secrete S1P.
The released S1P represents an important factor by which MSCs exert their paracrine stimulatory effects
on the proliferation of C2C12 myoblasts and satellite cells [227]. Interestingly, we have reported that
autocrine release of S1P by MSCs and S1PR1 activation exert a trophic role in maintaining the ability of
MSCs to modulate MMP-2 expression and function [228]. In the same study, we also demonstrated that
MMP-2 expression and release are necessary not only for ECM degradation, but also for cytoskeleton
reorganization and cell proliferation in both conditions of normoxia and hypoxia, which may resemble
a damaged/regenerating tissue microenvironment. These results appear of particular interest when
considering that all those cellular events may positively influence satellite cells behavior. Indeed,
it is tempting to speculate that released MMP-2 may contribute to ECM degradation favoring both
satellite cell migration, myoblast fusion, MSC recruitment (proliferation and migration) to the injury
site and also the release of ECM-tethered pro-myogenic factor (such as HGF) [178,202,229] (Figure 1).
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Furthermore, the occurrence of a potential interaction cannot be excluded between MMP-2 and
syndecan 4 [230], a cell-surface transmembrane heparan sulfate proteoglycan, whose regulatory role in
satellite cell maintenance, activation, proliferation and differentiation has been documented [231,232].
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Figure 1. Drawing representing the potential influence of S1P released in the context of damaged
skeletal muscle tissue by blood and different cells, via S1PRs in the regulation of mechanobiology of
satellite cell (SC) niche, namely, SC mechanotransduction events in response to ECM stiffness and
the modulation of ECM stiffness. The interplay between MSCs and SCs in such context has been
highlighted. Abbreviations not present in the text: exogenous S1P (i.e., not synthetized and released by
the target cell), exoS1P; gap junctions, GJ. Dotted lines: unknown pathways.
On the other hand, a role of S1P/S1PR signaling in the modulation of the functionality of
macrop ages and other inflammatory cells potentially invading t e damaged satellite niche, with
potential repercussion on stem cell behavior, has been widely demonstrated [233–236].
5.3. How S1P-S1PR Signaling May Influence Satellite Cell Mechanotrasduction Events: Actin Cytoskeleton as
a Key Target
Cyt skeleton, physically and/or functionally linked to different receptors or transcriptional factors
acting as mechanosensors in satellite cells, seems to be the key player in mechanotransduction, being
responsible f r relaying and moderating transcriptional eve ts in response to mechanical cues. It has
been reported that in response to stiff environment cytoskeleton network undergoes dynamic changes
mainly consisting in acto-myosin contractile stress fiber formation [10].
One of the referred mechanism by which stress fiber may regulate transcriptional events in satellite
cells is related to the depletion of G-actin pool after stress fiber formation. Indeed, G-actin is able to
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sequester some transcriptional factors, namely myocardin-related trascritpion factor (MRTF), and is
able to activate serum response factors, which are crucially involved in the expression of muscle specific
genes [237]. When the monomeric G-actin becomes polymerized into F-actin, within stress fibers, MRTF
are liberated and translocate to the nucleus [179,197]. In addition, contractile stress fibers, generating
an increase of intracellular tension, may contribute to the opening of mechanosensitive channels,
namely, Stretch Activated Channels (SACs), whose essential role in both early proliferative stage and
subsequent differentiation of skeletal muscle myoblasts have been described [198,217,219,238,239].
Given that the impact of S1P/S1PR on actin cytoskeleton dynamics in different cells including
muscle precursor cells has been widely demonstrated [228,240,241], it is reasonable to assert that this
signaling is involved in modulation of the satellite cell mechanotransduction. In this context, our research
group demonstrated that activation of S1P/S1PR signaling (Edg3/ S1PR3 and Edg 5/S1PR2) elicits robust
cytoskeletal rearrangement in murine C2C12 myoblastic cells, mainly consisting in the formation of stress
fibers and assembly of FAs through the activation of Rho-and phospholipase D (PLD)-mediated pathways.
These events were associated with an increase of intracellular calcium transients propagating throughout
the cytoplasm and nucleus as well as cell contractility [213,217,225,238,242–244]. Considering the reported
role of calcium in mechanotransduction in the skeletal muscle tissue [245], the potential involvement of
S1P/S1PR signaling in the mechanotransduction events in satellite cells via modulation of calcium transient
cannot be excluded.
Interestingly, we also revealed that S1P-induced stress fiber formation is associated with the
onset of plasmamembrane tension and the activation, in turn, of SACs [238,244]. The functional
interaction between stress fibers and SACs is required for myogenic differentiation of myoblasts [217].
Indeed, both the disruption of actin cytoskeleton and the impairment of channel functionality
hamper myogenesis.
Consistent with the assumption of the potential relevance of S1P/S1PR signaling in satellite cell
cytoskeleton mediated-mechanotransduction events correlated to myogenic differentiation, we showed
the ability of this signaling to promote the functional assembly at membrane of an essential component
of SACs, namely transient receptor potential canonical channel (TRPC)1 by the induction of stress fiber
formation. Concomitantly, S1P/S1PR signaling modulates also TRPC1 expression and the channel
activity, which are required for skeletal myoblast differentiation [219].
Furthermore, we have demonstrated that a key regulatory protein of C2C12 myoblast
differentiation elicited by S1P/S1PR signaling is connexin 43 (Cx43), one of connexin isoform forming
gap junctions. Interestingly, beside its gap junction-dependent function, we demonstrated that Cx43
may regulate skeletal muscle differentiation per se, acting as adaptor protein. This gap junction-
independent function requires the physical association of Cx43 with cytoskeletal protein (F-actin and
cortactin) and the cyoskeleton remodeling, events that are both elicited by S1P [215]. Interestingly,
Cx43/cytoskeleton interaction promoted by S1P during myoblast differentiation is dependent by
S1P-mediated TRPC1 activation [246].
Finally, emerging studies indicate that tension of the actomyosin cytoskeleton is required for the
regulation of YAP and TAZ, involved in the modulation of muscle stem cell function [14,200]. Therefore,
it is enticing to speculate that the cytoskeleton remodeling elicited by S1P/S1PR may impact also on
this nuclear relays of mechanical signals and therefore modulate satellite cell mechanotransduction
(Figure 1). On the other hand, a cytoskeleton-indipendent regulation of the Hippo system/YAP/TAZ by
the S1P/S1PR signaling in satellite cells as occurs in other cell types as stated in the Section 4.2, cannot
be excluded and is worth investigating.
5.4. How S1P-S1PR Signaling May Influence ECM Stiffness
As far as we know, direct evidence of the contribution of S1P/S1PR signaling in the modulation of
ECM stiffness in skeletal muscle with repercussion on satellite cell activities are lacking. Nevertheless,
its postulation appears reasonable on the basis of data revealing the impact of this signaling on
muscle ECM remodeling and on the capability of different cell types (likely occupying satellite cell
Int. J. Mol. Sci. 2019, 20, 5545 15 of 30
microenvironment, such as the same satellite cells, fibroblasts, myofibroblasts, MSCs, and even
inflammatory cells/macrophages) to synthetize and deposit fibrillar collagen and/or release MMPs.
Along this line, a study from our research group, aimed to examine the effects of S1P on ex-vivo murine
model of eccentric contraction (EC)-induced muscle damage, showed that the bioactive lipid attenuates
the intermyofiber deposition of collagen in damaged muscles and up-regulates the expression of
MMP-9, concomitantly stimulating the myogenic differentiation of the resident satellite cells [205],
thus, confirming the influence of ECM stiffness on satellite cell behavior.
The role of S1P/S1PR signaling in modulating the functionality of fibroblasts from different
tissues, including their ability to express and deposit collagen and synthetize MMPs, has been
demonstrated [247] as well as the impact of the signaling on the modulation of the transition of
fibroblasts towards myofibroblasts. Myofibroblast are the main cells responsible for formation of
provisional scar and its removal during reparative process/tissue scarring and, in the worst conditions,
of tissue fibrosis development [52,194,248–250].
For example, in the cardiac fibrosis context, SphK1 seems to be determinant [52,251]. In addition,
it has been demonstrated that the expression of this enzyme is promoted by the well-known pro-fibrotic
factor, namely Transforming Growth Factor (TGF)-β, and that the enzyme mediates the upregulation
of TIMP-1. Moreover, the SphK1 silencing results in the inhibition of collagen production elicited
by TGF-β [252,253]. Notably, the neutralization of extracellular S1P by a specific antibody, robustly
decreases TGF-β-stimulated collagen synthesis, indicating that the “inside-out” S1P signaling, upon
SphK1 activation, may play a role in the pro-fibrotic response [253]. However, at this point, it is worth
mentioning that TGF- β may act not only as a pro-fibrotic agent, it might also positively influence
stem cell recruitment and fate determination and ultimately regeneration and homeostasis of different
adult tissue [254]. In line with this, an increase of the expression of this factor and of its receptor
(type II receptor) in pancreatic acinar, ductal epithelial and islets cells during the early phases of
spontaneous pancreatic recovery after ischemia/reperfusion (I/R)-induced pancreatitis in rats, has been
observed [255,256]. The involvement of S1P/S1PR signaling in modulating such “non-canonical” role
of TGF-β in muscle tissue regeneration [257] is worth to be investigated.
It is tempting also to speculate that the contribution of S1P/S1PR signaling on ECM stiffness
may be linked to its involvement in the regulation of the expression and release of collagen and
MMPs in MSCs, based on the following recent observations: 1) S1P/S1PRs (including S1PR1/R3
but not S1PR2) have been proven to play an important role in the regulation of collagen type I/III
expression in mouse and human bone marrow-derived MSCs and on the acquisition of myofibroblastic
phenotype by these cells [258,259] and 2) S1P/S1PR1 is required for the gelatinolytic activity of MMPs
and for MMP-2 expression/function in murine bone marrow-derived MSCs [228] (Figure 1). Finally,
an impact of S1P/S1PR signaling on matrix degradation and remodeling capacity of macrophages can
be supposed [25,30,235,260–263].
6. S1P/S1PR and Modern Strategies for Regenerative Medicine
The modern strategies for regenerative medicine are based on the use of instructive biomaterials,
such as hydrogels or polymer scaffolds, which help in the specific delivery of cells or in forcing cells to
adopt a specific shape. Because of the peculiar functions of S1P in modulating the cell response to
mechanical stimuli described in this review, the possibility to localize or modulate the S1P content may
be a useful experimental approach to recruit stem/progenitor and effector immune cells in specific
location [264], while influencing their behavior.
The advantages of the utilization of S1P in regenerative medicine are extensively revised by Marycz
et al. [265,266]. Zheng et al. [267] were the first to show that material-controlled release of S1P could be
clinically relevant. In fact, Jurkat leukemic T cells overexpressing the receptor subtypes Edg-2 and
Edg-4 were able to differently migrate through a layer of Matrigel on a 5-um pore polycarbonate filter
upon anti-Edg-4 or anti-Edg-2 R antibodies, treatment providing the evidence of a receptor-selective
mechanisms for regulation of T cell recruitment and immune contributions.
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Many studies demonstrate the utility of S1P to functionalize biomaterials. In particular S1P can
be loaded on poly(lactic-co-glycolic acid) (PLGA), encapsulated within PLGA thin films or temporally
delivered from porous hollow cellulose fibers. S1P loaded onto functionalized biomaterials, was found
to enhance the osteogenic differentiation of human adipose-derived multipotent stromal stem cells [266]
or to potentiate the osteogenic capability of rat bone marrow stromal cells in vivo when the bioactive
lipid is coated on β-Tricalcium phosphate scaffold [268]. Other biomaterial systems, such as alginate
hydrogels, have been used for controlling S1P release in order to create a local continued concentration
gradients able to favor de novo vascularization [269]. Moreover, it has been documented that S1P-loaded
on microparticles of PLGA improves blood flow recovery [270] and promotes short-term enlargement
of arteriolar and venular diameters [271].
The biomimetic release of S1P in cultured MSCs can also be performed with chitosan-gelatin
scaffold functionalized with microspheres that offers higher stability [272]. To enhance the stability of
S1P effect, the bioactive lipid has been also co-delivered from PLGA films together with a S1P lyase
inhibitor, which limits the degradation of the bioactive lipid, thus substantially increasing its local
tissue concentrations over time [264].
Similarly, agonists/antagonists of S1PR have been loaded on specific matrix. For instance, hydrogels
containing micelles of the S1PR1 agonist, SEW2871, were demonstrated to enhance macrophage
migration in vitro as well as in vivo [273]. FTY720-loaded nanofibers have been successfully utilized
to increase bone regeneration ability, reduce vascularization and local inflammation in a rat model,
providing evidence for the use of S1P agonist in craniofacial defect recovery [274]. In addition,
FTY720 delivered in PLGA thin films resulted in a local recruitment of factors and monocytes in
inflamed and ischemic tissues [275].
Finally, the delivery of humanized anti-S1P monoclonal antibodies was found to be useful for
limiting the microvessel tube formation by human brain ECs obtained from patients with macular
degeneration and plated on Matrigel [276].
It is important to emphasize that the integration between biochemical factors together with
biomechanical stresses become crucial points to be considered when studying the ability of stem cells
to differentiate in specific cell lineage. In order to overcome the limits correlated to the traditional
methods of culturing cells mainly on stiff substrates, many novel technologies taking into account
these considerations are emerging in tissue regeneration and regenerative medicine field. The use
of three-dimensional (3D) culture conditions, especially cell-seeded scaffold systems, allows the
cells to reach a cell shape closer to the one of their natural environment [277]. Notably, the 3D
printing technologies, used with biocompatible materials and stem cells, may create a field of 3D
bioprinting for artificial organ printing [278], possibly opening new interesting windows in regenerative
medicine approach.
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